> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cabaletta Bio’s Rese-cel Keeps All 6 Dermatomyositis Patients Improving At One Year
- URL: https://www.bullished.co/cabaletta-bios-rese-cel-keeps-all-6-dermatomyositis-patients-improving-at-one-year-bea932b0/
- Published: 2026-11-09T11:21:43.000Z
- Updated: 2026-11-09T11:21:43.000Z
- Description: Small uncontrolled studies also showed lupus kidney responses and systemic sclerosis improvement, with a myositis approval filing planned for 2028.
- Author: Matteo Parrino
- Tags: SEC Filings, CABA, Industry: Healthcare

[Cabaletta Bio](https://www.bullished.co/tag/caba/), which develops engineered T cell treatments for autoimmune diseases, reported that [all 6 patients](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-20261109.htm?ref=bullished.co) with dermatomyositis retained moderate or major improvement a year after receiving experimental rese-cel, without immune-modulating drugs. The results, detailed in Monday’s SEC filing, come as the company pursues a myositis study intended to support an FDA approval application.

## Six Responses, Without A Control Group

Five of the six patients had reached that improvement level by week 16—the main assessment point in the ongoing approval-focused study. Most were also off steroids at week 52, and improvements extended to muscle strength, skin symptoms and patients’ assessments of fatigue and physical function.

The findings come from [early-to-mid-stage studies](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-ex99%5F1.htm?ref=bullished.co) in which everyone received treatment and there was no comparison group. Patients underwent preparatory treatment before a single infusion dosed according to body weight; the reported data run through September 4, 2026.

Rese-cel uses modified T cells to remove B cells, including those involved in autoimmune disease, where the immune system attacks healthy tissue. Cabaletta’s development program covers myositis, lupus, systemic sclerosis, generalized myasthenia gravis and pemphigus vulgaris.

David J. Chang, Cabaletta Bio’s chief medical officer, said the emerging findings support the treatment’s potential to “deliver an [immune reset](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-ex99%5F1.htm?ref=bullished.co) that leads to durable efficacy with a favorable benefit-risk profile for autoimmune disease patients.”

## Kidney Biopsies And Lung Improvement

All five lupus nephritis patients who chose repeat kidney biopsies met lupus remission criteria while taking no immune-modulating drugs and no or low-dose steroids. Their follow-up ranged from six months to two years, and every biopsy showed tissue-level response or remission.

Cabaletta argues that the biopsies can help distinguish ongoing disease from kidney damage that predates treatment. Some patients can continue to have protein in their urine without meeting complete kidney-response criteria, even when tissue findings show response or remission.

In systemic sclerosis, five of seven patients, or 71%, met the stricter composite improvement threshold at one year without immune-modulating drugs. Six of seven, or 86%, met the less stringent threshold, and skin scores also improved.

The five patients with interstitial lung disease had a 9% mean improvement in lung capacity measured against predicted values at one year. Cabaletta is enrolling an approval-focused systemic sclerosis cohort centered on patients with that lung condition.

## Safety Across 71 Patients

The safety analysis [covered 71 patients](https://markets.ft.com/data/announce/detail?dockey=1330-9872789en-611UOF1I3CIPHDMRA7ETBK726D&ref=bullished.co) receiving rese-cel after preparatory treatment across myositis, lupus, systemic sclerosis and myasthenia gravis. Of those, 94% had either no cytokine release syndrome—an inflammatory reaction—or only its mildest grade; 6% had moderate cases.

Associated neurological toxicity was absent in 96% of patients. The [detailed safety table](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-ex99%5F2.htm?ref=bullished.co) records three neurological cases, graded 1, 3 and 4, rather than an entirely mild safety experience. No cases of the additional inflammatory syndrome known as IEC-HS were reported.

Cabaletta expects results from its adult dermatomyositis and anti-synthetase syndrome study in the second half of 2027\. Both are forms of myositis; the planned FDA application would include adult dermatomyositis and all available early-to-mid-stage juvenile dermatomyositis data.

Cabaletta plans to submit that myositis approval application in the first quarter of 2028; rese-cel remains experimental.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Cabaletta Bio, Inc. (CABA)](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-20261109.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit caba-ex99\_1.htm — Cabaletta Bio, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit caba-ex99\_2.htm — Cabaletta Bio, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001759138/000175913826000050/caba-ex99%5F2.htm?ref=bullished.co) — SEC EDGAR
- [Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=1330-9872789en-611UOF1I3CIPHDMRA7ETBK726D&ref=bullished.co) — Financial Times
- [Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data](https://www.globenewswire.com/news-release/2026/11/08/3398000/0/en/cabaletta-bio-presents-new-rese-cel-phase-1-2-clinical-data-at-acr-convergence-2026-featuring-immunomodulator-free-durability-and-favorable-benefit-risk-profile-across-autoimmune-d.html?ref=bullished.co) — globenewswire.com
- [Cabaletta Bio Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/05/3396297/0/en/cabaletta-bio-reports-third-quarter-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com
- [Cabaletta Bio to Participate in Upcoming Investor](https://www.globenewswire.com/news-release/2026/11/03/3394149/0/en/cabaletta-bio-to-participate-in-upcoming-investor-conferences.html?ref=bullished.co) — globenewswire.com
- [Cabaletta Bio Reports Inducement Grants Under Nasdaq](https://www.globenewswire.com/news-release/2026/11/04/3395778/0/en/cabaletta-bio-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html?ref=bullished.co) — globenewswire.com

### More on Cabaletta Bio

- [Cabaletta Bio Has $299.4 Million To Carry Its Treatment Program Into 2028, Company Says](https://www.bullished.co/cabaletta-bio-has-299-4-million-to-carry-its-treatment-program-into-2028-company-says-dd6e7c93/)

[All Cabaletta Bio (CABA) coverage →](https://www.bullished.co/tag/caba/)